Prothena公共 PRTA 深 滬
已收盤 08-01 16:00:00 美东时间
6.81
-0.060
-0.87%
華盛通- 最 高6.87
- 今 開6.80
- 成交量 85.99万股
- 最 低 6.61
- 昨 收 6.87
- 總市值 3.67亿
- 52周最高 22.83
- 市盈率 靜 --
- 換手率 1.60%
- 52周最低 4.32
- 委 比 87.40%
- 總股本 5382.70万
- 歷史最高 79.749
- 量 比 0.95
- 振 幅 3.78%
- 歷史最低 4.32
- 每 手 1
- 風險率 5.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多A Glimpse of Prothena Corp's Earnings Potential
Prothena Corp (NASDAQ:PRTA) will release its quarterly earnings report on Monda...
08-02 05:05
Prothena Secures Leadership with New Executive Agreements
The latest update is out from Prothena ( ($PRTA) ). On July 30, 2025, Prothena ...
07-31 05:52
Roche's Itovebi combination for breast cancer gets EU nod
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF) said that the European Commission has approved its oral cancer drug, Itovebi (inavolisib), to be used alongside palbociclib and fulvestrant for breast c...
07-23 21:59
Roche COPD biologic astegolimab fails in phase 3 for COPD
Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...
07-22 02:52
FDA rejects Genentec's cancer drug label expansion
Genentech, part of the Roche Group (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF), announced that the U.S. FDA has rejected its request to expand the use of its cancer drug Columvi. The company had applied...
07-19 02:45
Roche's Genentech reports positive results from lymphoma trial
Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed improved outcomes for patients with relapsed or refractory large B-cell lymph...
06-21 02:01
8 Analysts Assess Prothena Corp: What You Need To Know
Across the recent three months, 8 analysts have shared their insights on Prothe...
06-20 22:00
Cantor Fitzgerald Reiterates Neutral on Prothena Corpto Neutral
Cantor Fitzgerald analyst Eric Schmidt reiterates Prothena Corp (NASDAQ:PRTA) from Neutral to Neutral.
06-20 21:14
Prothena Announces Major Workforce Reduction to Cut Costs
Prothena ( ($PRTA) ) has provided an update. On June 18, 2025, Prothena Corpora...
06-19 04:53
Prothena and Roche Move Parkinson's Drug to Phase III in Bid for First Disease-Modifying Treatment
Prothena Corporation plc (NASDAQ:PRTA) today announced partner Roche will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development in early-stage Parkinson's disease. This
06-16 19:34
